ArticleJournal of clinical hypertension (Greenwich, Conn.)2012
The role of nutraceutical supplements in the treatment of dyslipidemia.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 46 citations in OpenAlex.
- Metabolic Disease Management through Natural Products: A Thorough Exploration.Endocrine, metabolic & immune disorders drug targets · 2025Article
- Review
- Nutraceuticals in Paediatric Patients with Dyslipidaemia.Nutrients · 2022Review
- Association between plasma vitamin B5 and coronary heart disease: Results from a case-control study.Frontiers in cardiovascular medicine · 2022Article
- The Effects of Medicinal Plants and Bioactive Natural Compounds on Homocysteine.Molecules (Basel, Switzerland) · 2021Review
- Effect of a High-Protein High-Fibre Nutritional Supplement on Lipid Profile in Overweight/Obese Adults with Type 2 Diabetes Mellitus: A 24-Week Randomized Controlled Trial.Journal of nutrition and metabolism · 2021Article
- The Effect of Herbal Medicine and Natural Bioactive Compounds on Plasma Adiponectin: A Clinical Review.Advances in experimental medicine and biology · 2021Review
- Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells.Journal of biochemical and molecular toxicology · 2020Article
- The beneficial effects of nutraceuticals and natural products on small dense LDL levels, LDL particle number and LDL particle size: a clinical review.Lipids in health and disease · 2020Review
- Hyperuricemia and its association with adiposity and dyslipidemia in Northwest China: results from cardiovascular risk survey in Xinjiang (CRS 2008-2012).Lipids in health and disease · 2020Article
- Management of Statin Intolerance in 2018: Still More Questions Than Answers.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2018Review
- Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.Archives of medical science : AMS · 2017Article
- From Diabetes Care to Diabetes Cure-The Integration of Systems Biology, eHealth, and Behavioral Change.Frontiers in endocrinology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The combination of a lipid-lowering diet and scientifically proven nutraceutical supplements has the ability to significantly reduce low-density lipoprotein (LDL) cholesterol, increase LDL particle size, decrease LDL particle number, lower trigylcerides and very LDL levels, and increase total and high-density lipoprotein 2b cholesterol. In addition, inflammation, oxidative stress, and immune responses are decreased. In several prospective clinical trials, coronary heart disease and cardiovascular disease have been reduced with many nutraceutical supplements. This nutritional and nutraceutical supplement treatment is a valid alternative for patients who are intolerant to statins, cannot take other drugs for the treatment of dyslipidemia, or prefer alternative treatments. This new approach to lipid management to decrease vascular disease utilizes a functional medicine approach with a broader treatment program that will address the multitude of steps involved in lipid-induced vascular damage.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.